Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

As more biomarker-based tests become prevalent, options for identifying and treatment prostate cancer are going to expand. Prostate-specific antigen (PSA) screenings aren’t going away, says Carroll, but other types of testing should become standard in the future to reduce the amount of unnecessary biopsies.

Once a PSA has identified a high-risk patient, follow-up serum tests or imaging tests should be conduced to determine which patients will benefit from a biopsy. 

Peter R. Carroll, MD

Articles

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer